Jason Butler
Stock Analyst at JMP Securities
(3.15)
# 1,178
Out of 4,732 analysts
135
Total ratings
37.98%
Success rate
3.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PGEN Precigen | Reiterates: Market Outperform | $5 | $1.11 | +350.45% | 8 | Jan 14, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $45.74 | +70.53% | 13 | Jan 14, 2025 | |
| ARGX argenx SE | Maintains: Market Outperform | $606 → $696 | $640.52 | +8.66% | 7 | Jan 14, 2025 | |
| ABVX ABIVAX Société Anonyme | Initiates: Market Outperform | $33 | $6.16 | +435.71% | 1 | Dec 4, 2024 | |
| VIGL Vigil Neuroscience | Reiterates: Market Outperform | $22 | $1.93 | +1,039.90% | 4 | Nov 26, 2024 | |
| SYRS Syros Pharmaceuticals | Downgrades: Market Perform | n/a | $0.22 | - | 4 | Nov 13, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $72 → $73 | $54.80 | +33.21% | 13 | Nov 1, 2024 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Market Perform | n/a | $0.54 | - | 3 | Oct 24, 2024 | |
| AQST Aquestive Therapeutics | Reiterates: Market Outperform | $9 | $3.10 | +190.32% | 7 | Oct 8, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Market Outperform | $17 | $8.05 | +111.18% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $7 | $4.87 | +43.74% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $39 | $8.88 | +339.19% | 4 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.53 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $1.95 | +1,079.49% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $85 → $83 | $13.77 | +502.76% | 7 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $12.17 | +56.12% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $39 | $17.57 | +121.97% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $18.13 | +109.60% | 7 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $3.66 | +501.09% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.23 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $1,200 | $0.57 | +209,984.03% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $5.25 | +2,109.52% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.20 | +181.25% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $191 → $111 | $2.21 | +4,922.62% | 6 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.74 | - | 1 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $24 → $21 | $126.20 | -83.36% | 5 | Aug 8, 2019 |
Precigen
Jan 14, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $1.11
Upside: +350.45%
Cytokinetics
Jan 14, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $45.74
Upside: +70.53%
argenx SE
Jan 14, 2025
Maintains: Market Outperform
Price Target: $606 → $696
Current: $640.52
Upside: +8.66%
ABIVAX Société Anonyme
Dec 4, 2024
Initiates: Market Outperform
Price Target: $33
Current: $6.16
Upside: +435.71%
Vigil Neuroscience
Nov 26, 2024
Reiterates: Market Outperform
Price Target: $22
Current: $1.93
Upside: +1,039.90%
Syros Pharmaceuticals
Nov 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.22
Upside: -
Halozyme Therapeutics
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $54.80
Upside: +33.21%
Marinus Pharmaceuticals
Oct 24, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.54
Upside: -
Aquestive Therapeutics
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.10
Upside: +190.32%
Zevra Therapeutics
Sep 24, 2024
Initiates: Market Outperform
Price Target: $17
Current: $8.05
Upside: +111.18%
Sep 20, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $4.87
Upside: +43.74%
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $39
Current: $8.88
Upside: +339.19%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.53
Upside: -
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $1.95
Upside: +1,079.49%
May 9, 2024
Maintains: Market Outperform
Price Target: $85 → $83
Current: $13.77
Upside: +502.76%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $12.17
Upside: +56.12%
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $17.57
Upside: +121.97%
Nov 14, 2023
Maintains: Market Outperform
Price Target: $42 → $38
Current: $18.13
Upside: +109.60%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $3.66
Upside: +501.09%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.23
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $1,200
Current: $0.57
Upside: +209,984.03%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $5.25
Upside: +2,109.52%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.20
Upside: +181.25%
May 5, 2021
Maintains: Market Outperform
Price Target: $191 → $111
Current: $2.21
Upside: +4,922.62%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.74
Upside: -
Aug 8, 2019
Reiterates: Market Outperform
Price Target: $24 → $21
Current: $126.20
Upside: -83.36%